Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 356.24M P/E - EPS this Y 6.60% Ern Qtrly Grth -
Income -100.7M Forward P/E -3.76 EPS next Y -8.20% 50D Avg Chg 14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 1.76 EPS next 5Y - 52W High Chg -12.00%
Recommedations 1.30 Quick Ratio 10.18 Shares Outstanding 67.42M 52W Low Chg 235.00%
Insider Own 9.52% ROA -27.74% Shares Float 37.10M Beta 1.03
Inst Own 88.66% ROE -45.11% Shares Shorted/Prior 9.42M/6.93M Price 7.90
Gross Margin - Profit Margin - Avg. Volume 401,632 Target Price 19.14
Oper. Margin - Earnings Date May 6 Volume 224,550 Change -2.59%
About Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals, Inc. News
04/15/24 ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
04/08/24 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
04/05/24 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/04/24 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
03/26/24 How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
03/12/24 ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
03/11/24 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
03/08/24 ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares
03/06/24 ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
03/05/24 ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
02/14/24 ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
02/09/24 ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares
02/08/24 Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
01/23/24 Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
01/22/24 ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
01/09/24 Final Boarding Call: 3 Stocks Set for a Sky-High Surge
01/08/24 ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
04:30 PM ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/11/23 Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
12/05/23 3 Stocks at the Forefront of Personalized Medicine Trend
ORIC Chatroom

User Image IsabellaDC Posted - 04/18/24

Stocks that may have found their bottoms and have started the reversal --- but know how to draw a plan from these. ;) $APPS $BIGC $EHTH $LULU $ORIC and so on.

User Image DonCorleone77 Posted - 04/15/24

$ORIC Oric doses first patient in dose escalation portion of ORIC-114 trial Oric Pharmaceuticals announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications. Based upon these data, ORIC selected the two provisional recommended Phase 2 dose, or RP2D, levels of ORIC-114 at 80 mg and 120 mg QD, which are being further evaluated in three dose expansion cohorts for dose optimization and final RP2D selection. These expansion cohorts have now been initiated in patients with non-small cell lung cancer with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations. The company also announced the initiation of an extension cohort for the treatment of patients with first-line, treatment-naive EGFR exon 20 NSCLC.

User Image Stock_Titan Posted - 04/15/24

$ORIC ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-announces-first-patients-dosed-across-three-q8cq560ajd2h.html

User Image Stock_Titan Posted - 04/08/24

$ORIC ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-presents-preclinical-data-on-two-programs-at-aq1v4pk8vt6t.html

User Image Stock_Titan Posted - 04/05/24

$ORIC ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-nr91ln52ye0w.html

User Image Stock_Titan Posted - 04/04/24

$ORIC ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-u5acxqtemo3a.html

User Image DonCorleone77 Posted - 03/26/24

$ORIC Oric Pharmaceuticals price target lowered to $18 from $19 at JPMorgan JPMorgan lowered the firm's price target on Oric Pharmaceuticals to $18 from $19 and keeps an Overweight rating on the shares. The analyst updated the company's model to include expenses and share count.

User Image Quantumup Posted - 03/12/24

Oppenheimer raised⬆️PT $ORIC $17 was $14/Outperform~is pleased w/ Mgmt's execution, +g in strategic financing on heels of '114/'944 data; thinks '944 is >exciting, given higher unmet need/degree $PFE talking up its PRC2/EZH2 program, not2say '114 isn't interesting — sees approval playbook4 CNS lesions/beyond

User Image briefingcom Posted - 03/12/24

Gapping up in reaction to earnings/guidance: $RERE +31.9% $ORCL +12.8% $NNBR +11.4% $LFMD +11.1% $ORIC +4.9%

User Image Stock_Titan Posted - 03/11/24

$ORIC ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-2dke2k1xlryc.html

User Image AnomalyDetective Posted - 03/09/24

Week 11 MDA breakout picks for members with 3 out of 4 picks hitting 6 month highs on Friday. $ORIC saw peak gains of +22.8% last week and recent prior MDA picks continue in breakout with $CLSK +305.6%, $GCT +188.9%, $KOD +103.3% $YMAB +158.7% and more at www.vmbreakouts.com and https://seekingalpha.com/marketplace/1201-value-momentum-breakouts/subscribe

User Image Stock_Titan Posted - 03/06/24

$ORIC ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-to-present-at-the-leerink-partners-global-1j4kr3f6e95i.html

User Image AnomalyDetective Posted - 03/06/24

$ORIC hits 22% gains through Wednesday with multiple weekly breakout picks in double-digits again this week. New Week 11 MDA picks on Friday. As $AAPL $MSFT $GOOG decline the Weekly breakout picks up over 110% YTD more at vmbreakouts.com and here: https://seekingalpha.com/article/4660552-mda-breakouts-in-best-year-ever-new-picks-for-week-1-2024

User Image Irish_lass Posted - 03/06/24

$ORIC New 52

User Image Irish_lass Posted - 03/06/24

$ORIC

User Image shared_alerts Posted - 03/06/24

-03/06/2024- 📉 SCANNER UPDATE📈 $AISP $SMR $ULCC $ORIC ↩️

User Image Irish_lass Posted - 03/05/24

$ORIC https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-announces-multiple-presentations-2024

User Image Stock_Titan Posted - 03/05/24

$ORIC ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-announces-multiple-presentations-at-the-2024-kocaxkbasco7.html

User Image AnomalyDetective Posted - 03/05/24

$ORIC (Week 10 MDA) +14.5% for members through Tuesday in breakout reversal from negative Segment 2 with large buying volume approaching 2022 highs with room to run. New picks out Friday for Week 11 at https://t.co/KYh2p2mD5d and daily breakouts at vmbreakouts.com . Breakout results YTD: https://seekingalpha.com/marketplace/1201-value-momentum-breakouts/analysis/5993876-breakout-stock-performance-for-february-2024-mda-versus-bounce-lag

User Image shared_alerts Posted - 03/04/24

-03/04/2024- 📉 SCANNER UPDATE📈 $SGML $ORIC $SMR $BOWL ↩️

User Image tradingtwenty Posted - 2 months ago

$ORIC has trended 10 times in the past 24 hours (based on 5 minute intervals). Latest article on Mar 01, 2024 04:30 PM: ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Link: https://tradingtwenty.com/news/378064/oric-pharmaceuticals-reports-inducement-grantsunder-nasdaq-listing-rule-5635c4

User Image Ninja_Tradez Posted - 2 months ago

📢 $ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://newsfilter.io/a/36c915beb525fba9944f962d1ebbfbde

User Image Stock_Titan Posted - 2 months ago

$ORIC ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-8rmlgwgfrqd0.html

User Image NorthWestHawk Posted - 2 months ago

I plan to buy (or sell) ¼ $ORIC Long position after next $ORIC Earnings Release. $ORIC is estimated to report earnings on 03/21/202 AMC, per NASDAQ. Disclosures: 1️⃣ I'm currently holding a combined ~ 3/4 $ORIC Long position: at $8.5 (on 01/17/24), at $9.5 (on 1/19/24) and at $12.5 (on 2/9/24). These 3 purchases were not publicly posted on SS, although my last $ORIC post (at $12.6 on 2/9/24 - url attached) was very bullish and showed a weekly chart (also attached for convenience) with the triggered alerts at the 50-day SMA test, and at the $9.5 continuation; 2️⃣ Do not follow me if you don't understand risk management, diversification, at least basic #CANSLIM investing and basic #biotech investing; 3️⃣ POSTS ≠ ADVICE; https://stocktwits.com/NorthWestHawk/message/561089043 Recent #PIPE2watch $XBI #StocksToWatch 📈 #Bullish #Bitcoin #Pharma📈 #biotech #pharmaceutical #stockmarket

User Image _StockTrader Posted - 2 months ago

Real-Time Stock Data $ORIC Price: 14.28 Volume: 580275 Market Cap: 963535808 PE Ratio: -6.8428574 Stock data provided by: AITX

User Image NorthWestHawk Posted - 2 months ago

... and 3rd and last clue: Recent #biotech #PIPE2watch #dilution2watch #StocksToWatch (which stock will eventually 10X first: $PRME, $ORIC, $CRNX, $JANX or $APLT? None of them? Another biotech? - see my early morning post)

User Image shared_alerts Posted - 2 months ago

-03/01/2024- 📉 SCANNER UPDATE📈 $ORIC $EVGO $BIG $LVTX ↩️

User Image _www_larval_com_ Posted - 02/29/24

$ORIC has reverted -7% lower to 11% (~1Mv) in the last few minutes, 03/15 options, follow for more volatility.

User Image _StockTrader Posted - 02/29/24

Real-Time Stock Data $ORIC Price: 14.27 Volume: 1157530 Market Cap: 936782080 PE Ratio: -6.6528573 Stock data provided by: PSYC

Analyst Ratings
JP Morgan Overweight Mar 27, 24
HC Wainwright & Co. Buy Mar 21, 24
Oppenheimer Outperform Mar 12, 24
Wedbush Outperform Mar 12, 24
Baird Outperform Mar 12, 24
Wedbush Outperform Mar 1, 24
Cantor Fitzgerald Overweight Feb 23, 24
HC Wainwright & Co. Buy Dec 13, 23
HC Wainwright & Co. Buy Oct 26, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Sell 8.59 5,282 45,372 23,809 12/19/23
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Option 0 14,042 29,091 12/19/23
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Sell 8.58 5,282 45,320 83,809 12/19/23
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Option 0 14,042 89,091 12/19/23
Chacko Jacob President and CEO President and CEO Dec 15 Sell 8.58 14,539 124,745 808,544 12/19/23
Chacko Jacob President and CEO President and CEO Dec 15 Option 0 38,667 823,083 12/19/23
Chacko Jacob President and CEO President and CEO Jul 10 Sell 8.01 15,664 125,469 780,652 07/11/23
Chacko Jacob President and CEO President and CEO Jun 26 Sell 8.0281 20,000 160,562 800,652 06/28/23
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Option 0 6,041 9,512 12/16/22
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Sell 3.25 2,089 6,789 7,423 12/16/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Option 0 6,041 69,512 12/16/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Sell 3.25 2,089 6,789 67,423 12/16/22
Chacko Jacob President and CEO President and CEO Dec 15 Option 0 16,666 822,789 12/16/22
Chacko Jacob President and CEO President and CEO Dec 15 Sell 3.25 5,764 18,733 817,025 12/16/22
Chacko Jacob President and CEO President and CEO May 11 Buy 2.82 450,000 1,269,000 802,652 05/13/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Mar 31 Buy 5.3604 60,000 321,624 60,000 03/31/22
Chacko Jacob President and CEO President and CEO Mar 23 Buy 4.85 350,000 1,697,500 352,652 03/25/22
Heyman Richard A. Director Director Sep 16 Sell 25.04 1,388 34,756 216,272 09/16/21
Chacko Jacob President and CEO President and CEO Sep 16 Sell 25.05 8,156 204,308 2,652 09/16/21
Heyman Richard A. Director Director May 24 Sell 25.11 1,400 35,154 219,826 05/24/21
SCHELLER RICHARD H Director Director May 24 Sell 25.09 1,990 49,929 39,092 05/24/21
Chacko Jacob President and CEO President and CEO May 24 Sell 25.09 7,270 182,404 23,132 05/24/21
Heyman Richard A. Director Director May 18 Sell 25.23 5,874 148,201 221,226 05/18/21
Heyman Richard A. Director Director Apr 30 Sell 25.17 200 5,034 227,200 04/30/21
SCHELLER RICHARD H Director Director Apr 30 Sell 25.15 300 7,545 49,500 04/30/21
Chacko Jacob President and CEO President and CEO Apr 30 Sell 25.15 1,300 32,695 60,400 04/30/21
GORDON CARL L Director Director Mar 31 Sell 23.62 103,424 2,442,875 2,212,571 03/31/21
- - - Mar 31 Sell 23.62 103,424 2,442,875 2,212,571 03/31/21
GORDON CARL L Director Director Mar 26 Sell 24.46 112,298 2,746,809 2,315,995 03/26/21
GORDON CARL L Director Director Mar 23 Sell 25.75 32,940 848,205 2,428,293 03/23/21
- - - Mar 23 Sell 25.75 32,940 848,205 2,428,293 03/23/21